Camlin Fine Sciences Gestion
Gestion contrôle des critères 3/4
Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.
Informations clés
Ashish Dandekar
Directeur général
₹28.2m
Rémunération totale
| Pourcentage du salaire du PDG | 54.61% |
| Durée du mandat du directeur général | 19.3yrs |
| Propriété du PDG | 10.3% |
| Durée moyenne d'occupation des postes de direction | 4.6yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 5.6yrs |
Mises à jour récentes de la gestion
Recent updates
532834: Upcoming Meetings Will Support Bullish Outlook With Stable Forward Assumptions
Analysts have left the Camlin Fine Sciences price target unchanged at ₹182.5, explaining that a slightly lower discount rate and marginally higher profit margin assumptions are balanced by a modestly lower future P/E input. What's in the News Special and Extraordinary Shareholders Meeting scheduled via postal ballot in India on May 7, 2026, indicating upcoming shareholder decisions that may affect the company structure or capital plans (Key Developments).532834: Upcoming Meetings Will Support Confident Outlook Despite Revised Forecast Assumptions
Analysts have trimmed their price target on Camlin Fine Sciences from ₹235 to ₹182.5. This reflects updated assumptions around fair value, revenue growth, profit margins and future P/E expectations. What's in the News Board meeting scheduled for Feb 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).532834: Upcoming Results Meeting Will Reinforce Steady Assumptions Supporting Upside Potential
Analysts have kept the fair value estimate for Camlin Fine Sciences steady at ₹235, with only minor tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, resulting in a largely unchanged price target narrative. What's in the News Board meeting scheduled on February 13, 2026 to consider and approve the unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).532834: Scheduled Results Review Will Confirm Steady Assumptions Supporting Upside Potential
Analysts have kept their fair value estimate for Camlin Fine Sciences steady at ₹235, citing largely unchanged assumptions around revenue growth, profit margins and future P/E, with only minor tweaks to the discount rate and valuation inputs. What's in the News Board meeting scheduled for February 13, 2026, to review and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).532834: Upcoming Results Review Will Support Long Term Upside Potential
Analysts have adjusted their fair value estimate for Camlin Fine Sciences from ₹240 to ₹235, reflecting updated views on the discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News A board meeting is scheduled for February 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).532834: Upcoming Board And Director Decisions Will Support Long Term Upside
Analysts have maintained their fair value estimate for Camlin Fine Sciences at ₹240.00, with the small adjustments in discount rate and future P/E assumptions reflecting updated views on risk and valuation drivers rather than a change in the headline price target. What's in the News Board meeting scheduled for February 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).532834: Director Reappointment And Steady Assumptions Will Support Long Term Upside
Analysts have kept their fair value estimate for Camlin Fine Sciences steady at ₹240.0 per share, with the unchanged target reflecting consistent assumptions on revenue growth, profit margin and future P/E, alongside a slightly updated discount rate input. What's in the News A board meeting is scheduled for Nov 10, 2025, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended Sep 30, 2025, and to discuss other matters (Key Developments).532834: Governance Continuity And Stable Assumptions Will Support Long Term Upside
Analysts have kept their price target for Camlin Fine Sciences steady at ₹240.00. This reflects updated assumptions around a slightly higher discount rate and fine-tuned estimates for revenue growth, profit margin and future P/E, without a clear tilt in either a more optimistic or more cautious direction.532834: Share Swap And Governance Stability Will Drive Long Term Returns
Analysts have maintained their price target for Camlin Fine Sciences at ₹240.00, with only marginal tweaks to the underlying model inputs. This reflects steady confidence in the company’s growth and profitability trajectory.532834: Share Swap Acquisition Will Drive Long Term Returns
Analysts have modestly maintained their outlook on Camlin Fine Sciences, keeping the price target broadly unchanged near ₹240, as small tweaks to the discount rate and forward earnings assumptions continue to support a steady long term growth narrative. What's in the News Board meeting scheduled for November 10, 2025, to approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, and to consider the reappointment of Mahabaleshwar Palekar as a non executive independent director (Key Developments).532834: Share Swap Acquisition And Margin Expansion Will Drive Future Returns
Analysts have lowered their price target for Camlin Fine Sciences from ₹270 to ₹240. They cite updated estimates that reflect improved profit margins and revenue growth, along with a reduced valuation multiple.532834: Acquisition Plan Will Drive Shareholder Value Despite Margin Pressure
Analysts have revised their price target for Camlin Fine Sciences downward from ₹295 to ₹270. They cited lower expected profit margins, even though revenue growth is projected to be stronger.Tariff Benefits And Safety Trends Will Boost US And Europe
Key Takeaways Plant restarts and easing exceptional expenses are set to improve margins, with structural growth driven by global demand for compliant, high-quality food additives. Favorable trade barriers and China+1 supply diversification position Camlin Fine Sciences for market share gains, margin expansion, and reduced dependence on legacy products.Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | -₹141m |
| Sep 30 2025 | n/a | n/a | ₹187m |
| Jun 30 2025 | n/a | n/a | ₹825m |
| Mar 31 2025 | ₹28m | ₹15m | ₹685m |
| Dec 31 2024 | n/a | n/a | -₹2b |
| Sep 30 2024 | n/a | n/a | -₹2b |
| Jun 30 2024 | n/a | n/a | -₹1b |
| Mar 31 2024 | ₹29m | ₹15m | ₹651m |
| Dec 31 2023 | n/a | n/a | -₹8m |
| Sep 30 2023 | n/a | n/a | ₹350m |
| Jun 30 2023 | n/a | n/a | ₹674m |
| Mar 31 2023 | ₹26m | ₹14m | ₹577m |
| Dec 31 2022 | n/a | n/a | ₹581m |
| Sep 30 2022 | n/a | n/a | ₹628m |
| Jun 30 2022 | n/a | n/a | ₹442m |
| Mar 31 2022 | ₹20m | ₹12m | ₹650m |
| Dec 31 2021 | n/a | n/a | ₹598m |
| Sep 30 2021 | n/a | n/a | ₹465m |
| Jun 30 2021 | n/a | n/a | ₹579m |
| Mar 31 2021 | ₹18m | ₹11m | ₹510m |
| Dec 31 2020 | n/a | n/a | ₹394m |
| Sep 30 2020 | n/a | n/a | ₹291m |
| Jun 30 2020 | n/a | n/a | ₹302m |
| Mar 31 2020 | ₹18m | ₹11m | ₹303m |
Rémunération vs marché: La rémunération totale de Ashish ($USD 297.06K ) est supérieure à la moyenne des entreprises de taille similaire sur le marché Indian ($USD 184.92K ).
Rémunération et revenus: La rémunération de Ashish a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Ashish Dandekar (61 yo)
Mr. Ashish Subhash Dandekar serves as the Chairman of Board at Camlin Fine Sciences Limited since June 17, 2021. He has been the Managing Director of Camlin Fine Sciences Limited (formerly known as Camlin...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Chairman & MD | no data | ₹28.22m | 10.34% ₹ 2.5b | |
| MD & Director | 4.8yrs | ₹24.56m | 1.88% ₹ 458.0m | |
| Executive Director of Technical & Executive Director | no data | ₹11.98m | 0.10% ₹ 24.8m | |
| Chief Financial Officer | 9.2yrs | pas de données | pas de données | |
| Chief Operating Officer | 2.3yrs | pas de données | pas de données | |
| Company Secretary | 4.4yrs | ₹1.39m | pas de données | |
| Global Head of IT | no data | pas de données | pas de données | |
| Management Consultant | no data | pas de données | pas de données |
Gestion expérimentée: L'équipe de direction de 532834 est considérée comme expérimentée (ancienneté moyenne 4.6 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Chairman & MD | 19.3yrs | ₹28.22m | 10.34% ₹ 2.5b | |
| MD & Director | 11.7yrs | ₹24.56m | 1.88% ₹ 458.0m | |
| Executive Director of Technical & Executive Director | 7.8yrs | ₹11.98m | 0.10% ₹ 24.8m | |
| Independent Director | 1.2yrs | ₹600.00k | 0.068% ₹ 16.6m | |
| Non-Executive Non-Independent Director | 5.7yrs | pas de données | pas de données | |
| Non-Executive Independent Director | 4.5yrs | ₹2.45m | pas de données | |
| Non-Executive Non-Independent Director | 8.5yrs | ₹700.00k | 1.57% ₹ 383.3m | |
| Independent Director | 5.6yrs | ₹2.46m | pas de données | |
| Independent Non-Executive Director | 5.3yrs | ₹2.64m | 0.0031% ₹ 760.9k | |
| Independent Director | 6.7yrs | ₹2.18m | pas de données | |
| Independent Director | 1.1yrs | ₹125.00k | pas de données | |
| Non-Executive Non-Independent Director | 1.1yrs | pas de données | pas de données |
Conseil d'administration expérimenté: Les membres du conseil d'administration de 532834 sont considérés comme expérimentés (ancienneté moyenne 5.6 ans).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/04/30 10:37 |
| Cours de l'action en fin de journée | 2026/04/30 00:00 |
| Les revenus | 2025/12/31 |
| Revenus annuels | 2025/03/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Camlin Fine Sciences Limited est couverte par 9 analystes. 2 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Ankur Periwal | Axis Capital Limited |
| Abhishek Navalgund | Centrum Broking Limited |
| Satish Kumar | CGS International |